91
Participants
Start Date
December 19, 2019
Primary Completion Date
September 2, 2022
Study Completion Date
September 16, 2022
BDTX-189
Participants received a daily, oral dose of BDTX-189 as part of a 3 week cycle.
9215, New York
9236, New York
9209, Buffalo
7122, Pittsburgh
9112, Fairfax
9429, Madrid
9495, Madrid
9383, Madrid
9382, Madrid
9035, Atlanta
4080, Lake Mary
4100, Orlando
9501, Bordeau
9535, Plantation
4060, Sarasota
3000, Nashville
4107, Chattanooga
9476, Rennes
9510, Valencia
9173, Milwaukee
9525, Lille
9530, Rolling Meadows
9373, Lyon
9092, New Orleans
9003, Dallas
9117, Houston
9538, Webster
9250, Scottsdale
9512, Poitiers
9405, Long Beach
9474, Orange
9264, Portland
7141, New Haven
9203, Boston
9500, Copenhagen
9496, Barcelona
9363, Barcelona
9508, Barcelona
Lead Sponsor
Black Diamond Therapeutics, Inc.
INDUSTRY